Opportunity
Simpler Grants.gov #PAR-25-447
NHLBI TOPMed Omics Data Research Opportunity (No Funding Provided)
Buyer
National Institutes of Health
Posted
September 22, 2025
Respond By
May 08, 2028
Identifier
PAR-25-447
NAICS
541715, 541714
The National Heart, Lung, and Blood Institute (NHLBI) at NIH is inviting applications to leverage the TransOmics for Precision Medicine (TOPMed) program for research on heart, lung, blood, and sleep disorders. - Government Buyer: - National Institutes of Health (NIH) - National Heart, Lung, and Blood Institute (NHLBI) - Products/Services Requested: - Generation and integration of genetic and multi-omics data (including genomics, transcriptomics, proteomics, metabolomics, and epigenomics) - Data deposition into NIH-controlled databases (e.g., dbGaP, BioData Catalyst) - Unique/Notable Requirements: - No direct funding is provided under this opportunity - Applicants must use existing NHLBI-funded TOPMed resources - Data generated must be deposited in controlled-access NIH databases - Emphasis on advancing research from genetic association to functional genomics and personalized medicine - Use of AI and machine learning tools is encouraged - Broad eligibility: federal agencies, state/local governments, educational institutions, nonprofits, tribal organizations, and certain foreign entities - No specific OEMs or vendors are named, as this is a research grant opportunity, not a procurement of products or services.
Description
This Notice of Funding Opportunity (NOFO) invites applications to use the NHLBI-funded TransOmics for Precision Medicine (TOPMed) program to generate integrated genetic and multi-omics data to facilitate discovery of molecular mechanisms of Heart, Lung, Blood, and Sleep (HLBS) disorders. No funding will be provided under this NOFO. The genomic and related phenotypic data will be deposited in a public NIH-designated controlled-access database such as dbGaP and NHLBI's BioData Catalyst. The goal is to advance from cataloguing genetic associations to understanding genetic contributions to HLBS diseases at molecular and cellular levels, enabling functional genomics research and personalized medicine.